Molecular diagnostics of lung cancer for treatment stratification;Molekulardiagnostik zur Therapiestratifizierung des Lungenkarzinoms

Internist

Volumn 52, Issue 2, 2011, Pages 146-154

  Heukamp, L C ^a   Wolf, J ^a   Buttner R ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

EGFR; FGFR1; Lung cancer; Personalized medicine; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYBRID PROTEIN;

ARTICLE; CLINICAL TRIAL; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; SMOKING; SQUAMOUS CELL CARCINOMA; STRATIFICATION;

DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 79952534620     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-010-2698-y     Document Type: Article

References (31)

1. Alvarez JV, Greulich H, Sellers WR, et al. (2006) Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66:3162-3168
2. Batzer AG, Rotin D, Urea JM, et al. (1994) Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14:5192-5201
3. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648 (Pubitemid 46548951)
4. Eberhard DA, Johnson BE, Amler LC, et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909
5. Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043 (Pubitemid 46799492)
6. Gandhi J, Zhang J, Xie Y, et al. (2009) Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. PLoS ONE 4:e4576
7. Gee JM, Willsher PC, Kenny FS, et al. (1999) Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. Int J Cancer 84:54-61 (Pubitemid 29059109)
8. Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95:851-867 (Pubitemid 36833877)
9. Heukamp LC, Büttner R (2010) Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. Pathologe 31: 22-28
10. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27:4232-4235
11. Kobayashi S, Boggon TJ, Dayaram T, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792 (Pubitemid 40271173)
12. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26:1742-1751
13. Li AR, Chitale D, Riely GJ, et al. (2008) EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 10:242-248 (Pubitemid 351692167)
14. Li S, Schmitz KR, Jeffrey PD, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311 (Pubitemid 40544648)
15. Lièvre A, Bachet JB, Le Corre D, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995
16. Lin E, Li L, Guan Y, et al. (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7:1466-1476
17. Malden LT, Novak U, Kaye AH, Burgess AW (1988) Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48:2711-2714
18. Marchetti A, Milella M, Felicioni L, et al. (2009) Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 11:1084-1092
19. Mok TS, Wu YL, Thongprasert S, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
20. Paez JG, Jänne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500 (Pubitemid 38720929)
21. Pao W, Miller V, Zakowski M, et al. (2004) EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311 (Pubitemid 39209661)
22. Pao W, Miller VA, Politi KA, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
23. Riely GJ, Pao W, Pham D, et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844 (Pubitemid 43259866)
24. Sobol RE, Astarita RW, Hofeditz C, et al. (1987) Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 79:403-407 (Pubitemid 17126586)
25. Sos ML, Koker M, Weir BA, et al. (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69:3256-3261
26. Stoscheck CM, King LE (1986) Role of epidermal growth factor in carcinogenesis. Cancer Res 46:1030-1037 (Pubitemid 16048225)
27. Sung T, Miller DC, Hayes RL, et al. (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10:249-259 (Pubitemid 30181093)
28. Tsao MZC, Sakurada A, et al. (2006) An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 24:365
29. Weiss J, Sos ML, Seidel D, et al. (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1dependency in squamouscell lung cancer. Sci Transl Med 2:62ra93
30. Yamazaki H, Fukui Y, Ueyama Y, et al. (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8:1816-1820
31. Yun CH, Boggon TJ, Li Y, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227 (Pubitemid 46349842)